WO2019167983A1 - 医薬組成物、包装体及びその製造方法 - Google Patents
医薬組成物、包装体及びその製造方法 Download PDFInfo
- Publication number
- WO2019167983A1 WO2019167983A1 PCT/JP2019/007437 JP2019007437W WO2019167983A1 WO 2019167983 A1 WO2019167983 A1 WO 2019167983A1 JP 2019007437 W JP2019007437 W JP 2019007437W WO 2019167983 A1 WO2019167983 A1 WO 2019167983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- enzyme
- less
- titer
- container
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 91
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 238000000034 method Methods 0.000 title description 31
- 102000004190 Enzymes Human genes 0.000 claims abstract description 177
- 108090000790 Enzymes Proteins 0.000 claims abstract description 177
- 230000002414 glycolytic effect Effects 0.000 claims abstract description 87
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 29
- 238000003860 storage Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 abstract description 16
- 238000009472 formulation Methods 0.000 abstract description 8
- 229940088598 enzyme Drugs 0.000 description 168
- 239000000243 solution Substances 0.000 description 32
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 26
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 26
- 238000004108 freeze drying Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 13
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 13
- 244000005700 microbiome Species 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 206010019909 Hernia Diseases 0.000 description 12
- 208000033868 Lysosomal disease Diseases 0.000 description 10
- 208000015439 Lysosomal storage disease Diseases 0.000 description 10
- 208000002260 Keloid Diseases 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001969 hypertrophic effect Effects 0.000 description 9
- 210000001117 keloid Anatomy 0.000 description 9
- 201000006938 muscular dystrophy Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 231100000241 scar Toxicity 0.000 description 9
- 208000020431 spinal cord injury Diseases 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 description 8
- 206010023330 Keloid scar Diseases 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 230000000593 degrading effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012488 sample solution Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- -1 etc.) Proteins 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001523 saccharolytic effect Effects 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000588767 Proteus vulgaris Species 0.000 description 4
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 229920001515 polyalkylene glycol Polymers 0.000 description 4
- 229940007042 proteus vulgaris Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010022901 Heparin Lyase Proteins 0.000 description 3
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108010011519 keratan-sulfate endo-1,4-beta-galactosidase Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108010048429 chondroitinase B Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000488157 Escherichia sp. Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000589564 Flavobacterium sp. Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- 101710099863 N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 1
- 101710086247 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005443 coulometric titration Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 108010006406 heparinase II Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 108010015332 keratanase II Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/0202—Chondroitin-sulfate-ABC endolyase (4.2.2.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02021—Chondroitin-sulfate-ABC exolyase (4.2.2.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
Definitions
- the present invention relates to a pharmaceutical composition containing a glycolytic enzyme as an active ingredient, a package containing the same in a container, and a method for producing the same.
- compositions containing glycolytic enzymes as active ingredients are used in various disease fields.
- glycolytic enzyme such as Audrazyme®, Eraplace®, Nagrazyme®, Ripregal®, and Bimidim®
- the pharmaceutical composition for treating lysosomal diseases is commercially available as a liquid preparation for injection.
- International Publication No. 2012/081227 describes a therapeutic agent for intervertebral disc herniation containing a glycolytic enzyme (particularly chondroitinase ABC) as an active ingredient.
- freeze-dried preparations are superior in that logistics costs can be reduced.
- the titer of an enzyme may be greatly reduced by lyophilization, and it is even more so if the enzyme is in a trace amount. Therefore, when producing a lyophilized preparation, a device is devised so that a product having a desired enzyme activity can be produced.
- a device is devised so that a product having a desired enzyme activity can be produced.
- an enzyme that greatly exceeds the number of units required for a single dose is placed in a container and then lyophilized.
- a freeze-dried preparation is obtained.
- the administration liquid containing the active ingredient required for one administration is prepared by fractionating the amount required for administration.
- one aspect of the present invention is to provide a pharmaceutical composition containing a glycolytic enzyme as an active ingredient, wherein the decrease in titer associated with formulation by freeze-drying is suppressed. .
- the present inventors have found a means for providing a pharmaceutical composition containing a glycolytic enzyme capable of suppressing a decrease in titer before and after lyophilization, and have completed the present invention. .
- One aspect of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising a freeze-dried saccharolytic enzyme having a titer of 0.3 unit / ⁇ g or more as an active ingredient and a unit dose preparation having the enzyme amount of 2 ⁇ g or more and 8 ⁇ g or less.
- a freeze-dried saccharolytic enzyme having a titer of 0.3 unit / ⁇ g or more as an active ingredient and a unit dose preparation having the enzyme amount of 2 ⁇ g or more and 8 ⁇ g or less.
- Another aspect of the present invention is a method for producing a package comprising a pharmaceutical composition and a container for storing the pharmaceutical composition, the step of storing a solution containing 2 ⁇ g or more and 8 ⁇ g or less of a glycolytic enzyme in the container, Freeze-dried to obtain a unit dose pharmaceutical composition.
- a pharmaceutical composition containing a freeze-dried glycolytic enzyme in which a decrease in titer due to freeze-drying is greatly suppressed.
- process is not limited to an independent process, and is included in the term if the intended purpose of the process is achieved even when it cannot be clearly distinguished from other processes. .
- content of each component in a composition means the total amount of the said some substance which exists in a composition, unless there is particular notice, when the substance applicable to each component exists in a composition in multiple numbers.
- the pharmaceutical composition is a lyophilized preparation containing a glycolytic enzyme as an active ingredient.
- the pharmaceutical composition is a unit dose preparation containing lyophilized glycolytic enzyme having a titer of 0.3 unit / ⁇ g or more as an active ingredient, and the amount of the glycolytic enzyme is 2 ⁇ g or more and 8 ⁇ g or less.
- the “unit dose” is a necessary amount prepared for a single dose, and a unit dose preparation is obtained by formulating a pharmaceutical composition in a unit dose.
- a unit dose can contain, in addition to an effective amount, the replenishment amount necessary for preparing a single administration solution.
- the pharmaceutical composition In the pharmaceutical composition, the decrease in the titer of glycolytic enzyme due to freeze-drying is greatly suppressed. Moreover, the fall of the titer by storage is also suppressed significantly. Furthermore, since the pharmaceutical composition is a freeze-dried preparation prepared in advance for each unit dose, it is an excellent pharmaceutical composition from the viewpoint of convenience, hygiene, safety, etc. in the medical field.
- the package includes at least a container and a pharmaceutical composition accommodated in the container, and the pharmaceutical composition is accommodated in the container.
- “Saccharolytic enzyme” is not particularly limited as long as it can be used in medicine.
- glycolytic enzymes glycosaminoglycan degrading enzyme; glycosidase; peptide: N-glycanase (PNGaseF, endoglycosidase H, etc.), ⁇ -L-iduronidase, ⁇ -galactosidase, ⁇ -galactosidase, ⁇ -glucuronidase, ⁇ -Glucocerebrosidase, idursulfase, iduronic acid-2-sulfatase, N-acetylgalactosamine-6-sulfatase, N-acetylgalactosamine-4-sulfatase and the like.
- glycosaminoglycan degrading enzymes include keratanases such as keratanase I and keratanase II; heparinases such as heparinase I, heparinase II and heparinase III; -III, heparitinases such as heparitinase T-IV; chondroitinases such as chondroitinase ABC, chondroitinase ACI, chondroitinase ACII, chondroitinase ACIII, chondroitinase B, chondroitinase C; Examples include hyaluronidase and hyaluronidase such as hyaluronidase derived from streptococci. Examples of glycosidases include ⁇ -galactosidase and ⁇ -galactosidase derived from microorganisms.
- glycosaminoglycan degrading enzyme is used as the glycolytic enzyme.
- glycosaminoglycan degrading enzymes include hyaluronidase, chondroitinase, heparinase, keratanase, heparanase, heparitinase and the like.
- chondroitinase is preferable, chondroitinase ABC, chondroitinase B, chondroitinase ACI, and chondroitinase ACII are more preferable, and chondroitinase ABC is particularly preferable.
- Chondroitinase ABC may be a chondrase.
- the origin of the glycolytic enzyme is not particularly limited.
- a microbial glycolytic enzyme is employed.
- microorganisms include, for example, Bacillus sp., Escherichia sp., Pseudomonas sp., Flavobacterium sp., Proteus sp., Arthrobacter sp., Streptococcus sp., Bacteroides sp., Aspergillus sp.
- examples include the genus Myces.
- the glycolytic enzyme is chondroitinase ABC
- one derived from Proteus vulgaris for example, chondroitinase ABC derived from Proteus vulgaris
- chondroitinase ABC derived from Proteus vulgaris
- the method for producing a glycolytic enzyme is not particularly limited.
- An exemplary method for producing a glycolytic enzyme includes a step of obtaining a culture of microorganisms or animal cells that produce the glycolytic enzyme, and a step of recovering the glycolytic enzyme from the culture.
- the glycolytic enzyme produced by the microorganism may be one inherently possessed by the microorganism, or obtained by modifying the microorganism so as to produce the target enzyme by a genetic engineering technique described later. It may be a thing.
- the glycolytic enzyme is chondroitinase ABC
- it may be produced by culturing microorganisms such as Proteus vulgaris, etc., and produced by genetic engineering techniques using DNA or the like encoding chondroitinase ABC You may let them.
- the glycolytic enzyme may have the same amino acid sequence as that inherently possessed by an organism, but some amino acids are deleted, substituted and / or added as long as the desired purpose as a pharmaceutical product can be achieved. It may be equal.
- microorganism examples include, but are not limited to, those belonging to the genus Bacillus, Escherichia, Pseudomonas, Flavobacterium, Proteus, Arthrobacter, Streptococcus, Bacteroides, Aspergillus, Elizabetokingia, and Streptomyces. It can be illustrated.
- the growth conditions (medium, culture conditions, etc.) of the microorganism are appropriately selected according to the microorganism to be used, and can be arbitrarily set by those skilled in the art. By producing a saccharolytic enzyme using a microorganism, it is possible to produce a large amount at a lower cost than when a saccharolytic enzyme is produced using animal cells.
- the method for producing a glycolytic enzyme may include a step of introducing a recombinant vector expressing a gene encoding the target glycolytic enzyme into the host.
- a recombinant vector expressing a gene encoding the target glycolytic enzyme into the host.
- an appropriate expression vector such as a phage vector or plasmid vector
- the vector is appropriately selected according to the host cell. More specifically, such host-vector systems include E. coli and prokaryotic cells such as pET series, pTrcHis, pGEX, pTrc99, pKK233-2, pEZZ18, pBAD, pRSET, and pSE420.
- mammalian cells such as COS-7 cells and HEK293 cells
- expression vectors for mammalian cells such as pCMV series, pME18S series, and pSVL
- insect cells yeasts, Bacillus subtilis as host cells
- various vectors corresponding to these are exemplified.
- a vector constructed so as to express a fusion protein of a protein encoded by the incorporated gene and a marker peptide or a signal peptide can be used.
- the peptide include protein A, insulin signal sequence, His, FLAG, CBP (calmodulin binding protein), GST (glutathione-S-transferase) and the like.
- it is treated with restriction enzymes so that the inserted nucleic acid sequence and the vector can be ligated according to conventional methods, and blunting or ligation of the sticky ends is performed as necessary. Thereafter, the inserted nucleic acid sequence and the vector can be ligated.
- Transformation with a host vector can be performed by a conventional method.
- a vector can be introduced into a host and transformed by a method using a commercially available transfection reagent, a DEAE-dextran method, an electroporation method, a gene gun method, or the like.
- the growth conditions (medium, culture conditions, etc.) of microorganisms or animal cells that produce glycolytic enzymes are appropriately selected according to the microorganisms and cells used.
- a medium appropriately prepared with LB medium or the like as a main component can be used.
- COS-7 cells when used as host cells, they can be cultured at 37 ° C. using a DMEM medium containing about 2% (v / v) fetal calf serum.
- Recovery of the glycolytic enzyme from the growth can be performed by a known protein extraction / purification method according to the form of the glycolytic enzyme produced.
- the glycolytic enzyme when the glycolytic enzyme is produced in a soluble form secreted into the culture medium (culture supernatant), the culture medium may be collected and used as it is as a glycolytic enzyme.
- a method using a nitrogen cavitation device, homogenization, glass bead mill method, sonication, osmotic shock And extraction by cell disruption such as freeze-thaw method, surfactant extraction, or a combination thereof.
- Glycolytic enzymes are salted out, ammonium sulfate fractionation, centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography, gel permeation chromatography, affinity chromatography, You may refine
- Saccharolytic enzymes may be used alone or in combination of two or more.
- glycolytic enzymes are acetylated, polyalkylene glycolated (eg, polyethylene glycolated), alkylated, acylated, biotinylated, labeled (eg, labels for fluorescent materials, luminescent materials, etc.), phosphorylated, sulfated
- a conventionally known chemical modification group may be added.
- the pharmaceutical composition can include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes conventional excipients, binders, buffers, water for injection, isotonic agents, preservatives, soothing agents, etc. Is exemplified.
- Examples of the buffer include hydrochloric acid, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, phosphoric acid, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, aminoacetic acid,
- Examples include a buffer containing at least one kind of sodium benzoate, citric acid, sodium citrate, acetic acid, sodium acetate, tartaric acid, sodium tartrate, lactic acid, sodium lactate, ethanolamine, arginine, ethylenediamine, and dihydrogen phosphate Sodium and disodium hydrogen phosphate are preferred.
- tonicity agents examples include sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose, propylene glycol and the like.
- compositions include dextrans, sucrose, lactose, maltose, xylose, trehalose, mannitol, xylitol, sorbitol, inositol, serum albumin, gelatin, creatinine, polyalkylene glycol, nonionic Surfactants (for example, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, polyoxyethylene polyoxypropylene glycol) and the like, among which sucrose and / or polyalkylene glycol are preferable, Sucrose and / or polyethylene glycol are more preferred.
- nonionic Surfactants for example, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, polyoxyethylene polyoxypropylene glycol
- sucrose and / or polyalkylene glycol are preferable, Sucrose and / or polyethylene glycol are more preferred.
- the polyethylene glycol preferably has an average molecular weight of 200 or more and 25000 or less, more preferably a solid at room temperature, for example, an average molecular weight of 2000 or more and 9000 or less, more preferably 3000 or more and 4000 or less. preferable.
- examples of the polyethylene glycol include those having an average molecular weight of 3250, 3350, and 4000.
- the weight ratio of polyethylene glycol / sucrose is generally in the range of 1/10 to 10/1. The weight ratio is more preferably about 2/1.
- the “container” is not particularly limited as long as it can accommodate a pharmaceutical composition.
- the container include a syringe, a vial, an ampoule, and a syringe, and a vial is preferable.
- the material of the container include glass and plastic, and glass is preferable.
- the glass include borosilicate glass and soda lime glass.
- the container preferably further has a plug member or cap, and more preferably has a rubber plug.
- a container is not specifically limited, 0.5 mL or more and 100 mL or less are illustrated, 1 mL or more and 10 mL or less are preferable, 2 mL or more and 4 mL or less are more preferable, and 3 mL is still more preferable.
- the package in which the pharmaceutical composition is contained in a container may be filled with an inert gas such as nitrogen gas or argon gas, or may be deaerated.
- the water content of the freeze-dried preparation is, for example, 5% (w / w) or less, preferably 3% (w / w) or less, and more preferably 2% (w / w) or less.
- the water content is a value measured by a coulometric titration method.
- the amount of glycolytic enzyme per unit dose of the pharmaceutical composition is 2 ⁇ g or more and 8 ⁇ g or less.
- the lower the amount of the enzyme the more markedly the titer decreases before and after lyophilization.
- the amount of glycolytic enzyme per unit dose of the pharmaceutical composition is 2 ⁇ g or more and 7 ⁇ g or less, 2 ⁇ g or more and 6 ⁇ g or less, or 2.5 ⁇ g or more. 6 ⁇ g or less.
- the amount of glycolytic enzyme per unit dose of the pharmaceutical composition is 2 ⁇ g or more and 5 ⁇ g or less, or 2.5 ⁇ g or more and 5 ⁇ g or less. In a particularly preferred embodiment, the amount of glycolytic enzyme per unit dose of the pharmaceutical composition is 3 ⁇ g or more and 5 ⁇ g or less.
- the amount of glycolytic enzyme per container is 2 ⁇ g or more and 8 ⁇ g or less. In a more preferred embodiment, the amount of glycolytic enzyme per container is 2 ⁇ g or more and 7 ⁇ g or less, 2 ⁇ g or more and 6 ⁇ g or less, or 2.5 ⁇ g or more and 6 ⁇ g or less. In a more preferred embodiment, the amount of glycolytic enzyme per container is 2 ⁇ g or more and 5 ⁇ g or less, or 2.5 ⁇ g or more and 5 ⁇ g or less. In a particularly preferred embodiment, the amount of glycolytic enzyme per container is 3 ⁇ g or more and 5 ⁇ g or less.
- “Titer” means the activity (unit) of an enzyme with respect to 1 ⁇ g of a glycolytic enzyme, and is expressed in units / ⁇ g.
- the freeze-dried glycolytic enzyme has a titer of 0.3 (unit / ⁇ g) or more.
- the freeze-dried glycolytic enzyme has a titer of 0.3 (unit / ⁇ g) or more and 1 (unit / ⁇ g) or less.
- the titer of the lyophilized glycolytic enzyme is not less than 0.32 (unit / ⁇ g) and not more than 1 (unit / ⁇ g).
- the freeze-dried glycolytic enzyme has a titer of 0.34 (unit / ⁇ g) or more and 1 (unit / ⁇ g) or less. In a further preferred embodiment, the freeze-dried glycolytic enzyme has a titer of 0.36 (unit / ⁇ g) or more and 1 (unit / ⁇ g) or less. In another particularly preferred embodiment, the lyophilized glycolytic enzyme has a titer of 0.38 (unit / ⁇ g) or more and 1 (unit / ⁇ g) or less.
- the lyophilized glycolytic enzyme has a titer of 0.3 (unit / ⁇ g) or more and 0.5 (unit / ⁇ g) or less. In another embodiment, the titer of the lyophilized glycolytic enzyme is not less than 0.36 (unit / ⁇ g) and not more than 0.5 (unit / ⁇ g).
- Unit (U, unit) indicates the activity of a glycolytic enzyme, and 1 U is a degradation product equivalent to 1 micromole from a substrate per unit time under optimum temperature and optimum pH conditions. Is the amount that liberates.
- the glycolytic enzyme is chondroitinase ABC
- one unit is 1 from sodium chondroitin sulfate (chondroitin sulfate sodium salt that conforms to Japanese Pharmacopoeia Standard 2002) under conditions of pH 8.0 and 37 ° C. It means the amount that liberates 1 micromole of unsaturated disaccharide per minute.
- the enzyme activity per unit dose (enzyme activity of glycolytic enzyme) is, for example, 4 units or less. In another embodiment, the enzyme activity per unit dose is, for example, 0.1 unit or more and 4 units or less. In a preferred embodiment, the enzyme activity per unit dose is 0.5 units or more and 3 units or less. In a more preferred embodiment, the enzyme activity per unit dose is 0.9 unit or more and 3 units or less, or 0.9 unit or more and 2.5 units or less. In another preferred embodiment, the enzyme activity per unit dose is 0.9 unit or more and 2 units or less, 1.25 unit or more and 2 units or less, or 1.5 units.
- the enzyme activity per container is, for example, 4 units or less. In another embodiment, the enzyme activity per container is, for example, 0.1 unit or more and 4 units or less. In a preferred embodiment, the enzyme activity per container is 0.5 unit or more and 3 units or less. In a more preferred embodiment, the enzyme activity per container is 0.9 unit or more and 3 units or less, or 0.9 unit or more and 2.5 units or less. In another preferred embodiment, the enzyme activity per container is 0.9 unit or more and 2 units or less, 1.25 unit or more and 2 units or less (for example, 1.5 units).
- a pharmaceutical composition in the form of a lyophilized unit dose preparation containing a small amount (2 ⁇ g or more and 8 ⁇ g or less) of a glycolytic enzyme having a high titer (0.3 unit / ⁇ g or more).
- the enzyme activity of the glycolytic enzyme contained in the pharmaceutical composition in the form of a freeze-dried preparation is, for example, 75% or more and 80% or more when the value of the enzyme activity before freeze-drying is 100%. It is preferably 85% or more, more preferably 90% or more. If this is 100%, the enzyme activity values are equal before and after lyophilization.
- a pharmaceutical composition having storage stability of 12 months or more can be provided.
- the pharmaceutical composition has a storage stability of 24 months or longer, and in a more preferred embodiment, the pharmaceutical composition has a storage stability of 36 months or longer.
- the upper limit of storage stability is not particularly limited, but may be, for example, 48 months or less (for example, 36 months or less).
- “having storage stability” means predetermined conditions (for example, 12 months or more at 5 ° C. ⁇ 3 ° C., 6 months or more at 25 ° C. ⁇ 2 ° C., or 3 months or more at 40 ° C. ⁇ 2 ° C. or It means that the titer (%) after being stored in the dark for 6 months or longer is maintained to a pharmaceutically acceptable level.
- “storage stability” is evaluated by, for example, the residual titer rate (%).
- the residual titer ratio after storing the sample for 12 months or more while shielding light at 5 ° C. ⁇ 3 ° C. is, for example, 90% or more, and preferably 95% or more.
- the residual titer rate after storing the sample for 24 months or more while shielding light at 5 ° C. ⁇ 3 ° C. is, for example, 90% or more, and preferably 95% or more.
- the residual titer ratio after storing the sample for 36 months or longer with light shielding at 5 ° C. ⁇ 3 ° C. is, for example, 90% or more, and preferably 95% or more.
- the residual titer ratio after storing the sample for 6 months or more while shielding light at 25 ° C. ⁇ 2 ° C. is, for example, 90% or more, and preferably 95% or more.
- the residual titer rate after the sample is stored in the dark at 40 ° C. ⁇ 2 ° C.
- the residual titer after storing the sample at 40 ° C. ⁇ 2 ° C. for 6 months or more is, for example, 65% or more, preferably 70% or more, and more preferably 75% or more.
- the “titer residual ratio (%)” means that the pharmaceutical composition or package according to the present invention is subjected to conditions at a predetermined temperature (for example, 5 ° C. ⁇ 3 ° C., 25 ° C. ⁇ 2 ° C. or 40 ° C. ⁇ 2 ° C.).
- the titer (%) after being stored while being shielded from light below is a value calculated with the titer at the start of storage as 100%. If this is 100%, the value of enzyme activity is equal before and after the start of storage.
- a pharmaceutical composition having an effective period of 12 months or more can be provided.
- it is a pharmaceutical composition having an effective period of 24 months or longer, and in a more preferred embodiment, it is a pharmaceutical composition having an effective period of 36 months or longer.
- the upper limit of the effective period is not particularly limited, and may be, for example, 48 months or less (for example, 36 months or less).
- the “effective period” means a certain storage method (for example, 5 ° C. ⁇ 3 ° C. under shading, 25 ° C. ⁇ 2 ° C. under shading or 40 ° C. ⁇ from the time when the medicinal product is confirmed to be useful. When stored at 2 ° C. under shading), it means a period during which the same usefulness as a medicinal product at the time of confirmation can be expected.
- the pharmaceutical composition may include “a pharmaceutical composition contained in a container”.
- the pharmaceutical composition contained in the container comprises a unit dose of glycolytic enzyme.
- the use of the pharmaceutical composition various known uses can be selected as the use of the glycolytic enzyme.
- the use of the pharmaceutical composition containing a glycolytic enzyme as an active ingredient is not particularly limited, and examples include treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury.
- the pharmaceutical composition is used for the treatment of hernias.
- it is used for the treatment of disc herniation (eg, lumbar disc herniation).
- treatment includes not only complete cure but also improvement of some or all symptoms of the disease, and suppression of the progression of the disease (including maintenance and reduction in the rate of progression) and prevention.
- prevention includes preventing the occurrence of various symptoms in advance when various symptoms associated with the disease have not occurred.
- prevention refers to, for example, preventing the occurrence of an organic lesion in advance when there are various symptoms associated with the disease even though no clear organic lesion has been observed. Inhibiting the development of unsymptomd symptoms.
- an active ingredient and “effective amount” are amounts that are commensurate with a reasonable risk / benefit ratio, and have a desired level without excessive adverse side effects (toxicity, irritation, etc.). Meaning the amount of a component sufficient to obtain a response.
- the “as an active ingredient” and “effective amount” can vary depending on various factors such as symptoms, physique, age, and sex of the patient to be administered. However, those skilled in the art need not conduct individual tests for each combination of elements, but based on the results of one or more specific test examples and common general knowledge, the effective amount in other cases Can be determined.
- patient means an animal, preferably a mammal (eg, human, mouse, rat, hamster, guinea pig, rabbit, dog, cat, horse, etc.), more preferably a human.
- mammal eg, human, mouse, rat, hamster, guinea pig, rabbit, dog, cat, horse, etc.
- the pharmaceutical composition contained in the container is provided in a sterile state.
- the sterilization method of the pharmaceutical composition is not particularly limited, and can be performed by a conventionally known method such as filtration sterilization or dry heat sterilization.
- the administration form of the pharmaceutical composition is not particularly limited, and can be appropriately selected according to the disease to be treated, symptoms, severity, patient attributes (for example, age, etc.) and the like.
- the lyophilized preparation can be used by dissolving in any solvent (for example, water for injection, physiological saline, etc.).
- examples of the administration form include any administration route such as intravertebral injection, intravenous injection, intramuscular injection, subcutaneous injection, and infusion.
- the dose of the pharmaceutical composition can also be appropriately determined by those skilled in the art depending on the disease to be treated, symptoms, severity, patient attributes (eg, age, etc.) and the like.
- Kit In one embodiment, a package comprising the pharmaceutical composition contained in a container, and the pharmaceutical composition for the treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury
- a kit is provided that includes a package insert or label explaining the use of
- kits describes the use of the pharmaceutical composition for the treatment of herniosis, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury, as well as a package comprising the pharmaceutical composition contained in a container. It only needs to contain a document or label. That is, it may further contain other components.
- One aspect of the present invention is a method for manufacturing a packaged body in which a pharmaceutical composition is contained in a container, and includes a first step of storing a solution containing 2 ⁇ g or more and 8 ⁇ g or less of a glycolytic enzyme in a container. And a second step of lyophilizing the solution to obtain a unit dose pharmaceutical composition.
- the solvent used for the preparation of the solution containing the glycolytic enzyme is not particularly limited, and for example, a buffer solution such as water, physiological saline, or phosphate buffer may be employed.
- the solution may contain a pharmaceutically acceptable carrier as described above.
- the pH of the solution containing the glycolytic enzyme contained in the container is not particularly limited, but is preferably in the range of 6.5 to 7.5.
- a solution containing a glycolytic enzyme is accommodated in a container so that the enzyme activity per container is 4 units or less.
- the solution is stored in a container so that the enzyme activity per container is 0.5 unit or more and 4 units or less.
- the solution is stored in a container so that the enzyme activity per container is 1 unit or more and 3 units or less.
- the solution is stored in the container so that the enzyme activity per container is 1.25 units or more and 2.5 units or less.
- the second step includes a freeze-drying step in which a solution containing a glycolytic enzyme is frozen and moisture is removed by sublimation in the frozen state to dry the solution.
- drying is performed until the water content of the pharmaceutical composition after lyophilization becomes, for example, 5% (w / w) or less.
- the drying in the second step is preferably performed until the water content of the pharmaceutical composition after freeze-drying is 3% (w / w) or less, and is preferably performed until it is 2% (w / w) or less. More preferred.
- Another aspect of the present invention is the use of a unit dose formulation in the manufacture of a pharmaceutical composition for use in the treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury, with a titer of 0 It also includes the use of a unit dose preparation containing lyophilized glycolytic enzyme of 3 units / ⁇ g or more as an active ingredient, and the amount of the glycolytic enzyme is 2 ⁇ g or more and 8 ⁇ g or less.
- a unit dose formulation in the treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury, wherein the titer is 0.3 units / ⁇ g or more
- the titer is 0.3 units / ⁇ g or more
- the unit dose preparation containing the produced glycolytic enzyme as an active ingredient, and the amount of the glycolytic enzyme is 2 ⁇ g or more and 8 ⁇ g or less.
- a unit dosage formulation for use in the treatment of hernias, lysosomal diseases, keloids, hypertrophic scars, muscular dystrophy, or spinal cord injury with a titer of 0.3 units / ⁇ g or more
- a unit dose preparation containing dried glycolytic enzyme as an active ingredient and having an amount of the above-mentioned glycolytic enzyme of 2 ⁇ g to 8 ⁇ g is also included.
- a pharmaceutical composition comprising a freeze-dried saccharide-degrading enzyme having a titer of 0.3 unit / ⁇ g or more as an active ingredient and a unit dose preparation having a glycolytic enzyme amount of 2 to 8 ⁇ g.
- ⁇ 3> The pharmaceutical composition according to ⁇ 1> or ⁇ 2>, wherein the enzyme activity of the glycolytic enzyme is 75% or more when the value before freeze-drying is 100%.
- ⁇ 4> The pharmaceutical composition according to any one of ⁇ 1> to ⁇ 3>, which has a storage stability of 12 months or more at 5 ° C. ⁇ 3 ° C.
- ⁇ 5> The pharmaceutical composition according to any one of ⁇ 1> to ⁇ 4>, wherein the glycolytic enzyme is a glycosaminoglycan degrading enzyme.
- ⁇ 6> The pharmaceutical composition according to ⁇ 5>, wherein the glycosaminoglycan degrading enzyme is chondroitinase.
- chondroitinase is chondroitinase ABC.
- composition according to any one of ⁇ 1> to ⁇ 7>, comprising a pharmaceutically acceptable carrier.
- composition according to ⁇ 8> wherein the carrier comprises at least one of polyalkylene glycol and sucrose.
- ⁇ 10> The pharmaceutical composition according to any one of ⁇ 1> to ⁇ 9>, wherein the pharmaceutical composition is used for treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury.
- ⁇ 11> A package in which the pharmaceutical composition according to any one of ⁇ 1> to ⁇ 10> is contained in a container.
- ⁇ 12> The package according to ⁇ 11>, wherein the container is a vial, a syringe, or an ampoule.
- ⁇ 13> A package in which the pharmaceutical composition according to any one of ⁇ 1> to ⁇ 10> is contained in a container, and treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury
- a kit comprising a package insert or label explaining the use of said pharmaceutical composition for.
- a method for producing a package in which a pharmaceutical composition is contained in a container a step of containing a solution containing 2 ⁇ g or more and 8 ⁇ g or less of a glycolytic enzyme in a container; Obtaining a pharmaceutical composition.
- ⁇ 15> The production method according to ⁇ 14>, wherein the lyophilized glycolytic enzyme has a titer of 0.3 (unit / ⁇ g) or more.
- ⁇ 17> The production according to any one of ⁇ 14> to ⁇ 16>, wherein the enzyme activity of the glycolytic enzyme after lyophilization is 75% or more when the enzyme activity before lyophilization is 100%.
- ⁇ 18> The production method according to any one of ⁇ 14> to ⁇ 17>, wherein the glycolytic enzyme is a glycosaminoglycan degrading enzyme.
- glycoaminoglycan degrading enzyme is chondroitinase
- chondroitinase is chondroitinase ABC.
- ⁇ 21> The production method according to any one of ⁇ 14> to ⁇ 20>, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
- ⁇ 22> The production method according to ⁇ 21>, wherein the carrier contains at least one of polyalkylene glycol and sucrose.
- ⁇ 23> The method according to any one of ⁇ 14> to ⁇ 22>, wherein the pharmaceutical composition is used for treatment of hernia, lysosomal disease, keloid, hypertrophic scar, muscular dystrophy, or spinal cord injury.
- ⁇ 24> The method according to any one of ⁇ 14> to ⁇ 23>, wherein the container is a vial, a syringe, or an ampoule.
- chondroitinase ABC Chondroitinase ABC was prepared according to the method described in JP-A-6-153947. That is, it was produced by purifying from the culture supernatant of Proteus vulgaris. The titer of the obtained chondroitinase ABC was 0.4 U / ⁇ g.
- the enzyme activity of chondroitinase ABC was measured by the following method.
- the enzyme sample (chondroitinase ABC) was diluted 4000 times with 0.01% (w / v) casein reagent (20 mM phosphate buffer).
- 400 ⁇ L of substrate solution (3 mg / ml sodium chondroitin sulfate ester (Japanese Pharmacopoeia Standard), 50 mM 2-amino-2-hydroxymethyl-1,3-propanediol, 50 mM sodium acetate, pH 8 ) was added and mixed.
- the solution was reacted at 37 ° C.
- the sample solution, per the standard solution and the control solution, the ultraviolet-visible absorbance measurement method, the absorbance A T at a wavelength of 232 nm, the A S, and A B was measured to determine the enzyme solution activity (U / mL) by the following equation.
- the enzyme solution activity is the enzyme activity per unit liquid volume.
- a T Absorbance of sample solution
- a B Absorbance of control solution
- a S Absorbance of standard solution
- 1 U (unit) is defined as the value of the enzyme activity that catalyzes the reaction that liberates 1 micromole of unsaturated disaccharide per minute under the above reaction conditions.
- the value of the enzyme activity used in this specification was determined based on the enzyme solution activity.
- the enzyme amount (protein amount, ⁇ g) of chondroitinase ABC was measured by the following Lowry method (Lowry method). That is, 2.5 mL of an alkaline copper reagent was added to 0.5 mL of an enzyme sample (chondroitinase ABC) diluted 50-fold with pure water and mixed, and the mixture was allowed to stand at room temperature (20 ° C. to 25 ° C.) for 10 minutes. To this solution, 0.25 mL of a 1 mol / L phenol reagent was added and mixed, and allowed to stand at room temperature for 30 minutes to prepare a sample solution.
- Lowry method Lowry method
- the same operation as for the diluted enzyme sample was performed to obtain a standard solution.
- the same operation as the enzyme sample diluted 50 times was performed on 0.5 mL of water to obtain a blank solution.
- the light absorbency in wavelength 750nm was measured.
- the absorbance of the standard solution and the protein concentration were plotted by a linear regression method, and a standard curve that approximated each point was obtained.
- the amount of protein in the sample solution was determined from the obtained standard curve and the absorbance of the sample solution.
- chondrotinase ABC solution prepared using the enzyme buffer was placed in a 3 ml glass vial (manufactured by SCHOTT) so that the amount of the enzyme was as follows: Sample 1: 1.3 ⁇ g / vial (0.5 U / vial) Sample 2: 2.5 ⁇ g / vial (1.00 U / vial) Sample 3: 5.0 ⁇ g / vial (2.00 U / vial) Sample 4: 9.1 ⁇ g / vial (3.63 U / vial)
- the enzyme solution contained in these vials was freeze-dried under the following conditions (water content 2% (w / w) or less). After lyophilization, the inside of the vial was decompressed with nitrogen gas, and a rubber stopper was stoppered to obtain a unit dose preparation.
- Step 1 The temperature was cooled from room temperature to minus 35 ° C. under normal pressure, and the sample was frozen.
- Step 2 Temperature minus 35 ° C. and normal pressure were maintained for 30 minutes.
- Process 3 The state of temperature minus 35 ° C. and vacuum of 13.3 Pa was maintained for 5 hours.
- Process 4 The temperature was raised from minus 35 ° C. to 25 ° C. while maintaining the degree of vacuum at 13.3 Pa.
- Step 5 The temperature of 25 ° C. and the degree of vacuum of 13.3 Pa were maintained for 5 hours.
- the enzyme activity (U / unit dose) after lyophilization was measured for each vial.
- the titer (U / ⁇ g) and relative enzyme activity (enzyme activity after lyophilization when the enzyme activity before lyophilization was taken as 100%) (%) were calculated. The results are shown in Table 1.
- the enzyme activity (U / vial) after lyophilization was measured for the obtained unit dose preparation. As a result, the enzyme activity of 1.5 U / vial was maintained even after lyophilization.
- ⁇ Test Example 3> A unit dose formulation (1.5 U / vial) was obtained according to the method of Test Example 1. The resulting unit dose formulation was stored under conditions 1 or 2 below. The enzyme titer after each storage period was determined.
- Condition 1 25 ° C. ⁇ 2 ° C.
- light shielding Condition 2 5 ° C. ⁇ 3 ° C., light shielding
- the residual titer rate was 95% or more when the titer at the start of storage was 100% in the first, third and sixth months after the start of storage.
- the residual titer rate was 95% or more when the titer at the start of storage was 100% at 3 months, 6 months, 12 months, 24 months and 36 months after the start of storage.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
医薬組成物は、糖分解酵素を有効成分として含む凍結乾燥製剤である。医薬組成物は、力価が0.3ユニット/μg以上である凍結乾燥された糖分解酵素を有効成分として含み、前記糖分解酵素量が2μg以上8μg以下の単位用量製剤である。本明細書において「単位用量」は、1回の投薬のために用意される必要量であり、単位用量製剤は医薬組成物が単位用量で製剤化されてなる。単位用量は、有効量に加えて、1回の投与液調製のために必要な増仕込み量を含み得る。
有効成分: コンドロイチナーゼABC
単位用量あたりの酵素量: 2μg以上7μg以下
酵素力価: 0.36(ユニット/μg)以上1(ユニット/μg)以下
単位用量あたりの酵素活性: 0.9ユニット以上3ユニット以下
適用: 椎間板ヘルニア
有効成分: コンドロイチナーゼABC
単位用量あたりの酵素量: 2μg以上5μg以下
酵素力価: 0.36(ユニット/μg)以上0.5(ユニット/μg)以下
単位用量あたりの酵素活性: 0.9ユニット以上2.5ユニット以下
適用: 椎間板ヘルニア
有効成分: コンドロイチナーゼABC
単位用量あたりの酵素量: 2μg以上5μg以下
酵素力価: 0.36(ユニット/μg)以上0.5(ユニット/μg)以下
単位用量あたりの酵素活性: 0.9ユニット以上2ユニット以下
適用: 椎間板ヘルニア
有効成分: コンドロイチナーゼABC
単位用量あたりの酵素量: 2μg以上5μg以下
酵素力価: 0.36(ユニット/μg)以上0.5(ユニット/μg)以下
単位用量あたりの酵素活性: 1.25以上2ユニット以下
適用: 椎間板ヘルニア
有効成分: コンドロイチナーゼABC
単位用量あたりの酵素量: 3μg以上5μg以下
酵素力価: 0.36(ユニット/μg)以上0.5(ユニット/μg)以下
単位用量あたりの酵素活性: 1.5ユニット
適用: 椎間板ヘルニア
一実施形態では、前記医薬組成物が容器に収容されてなる包装体、およびヘルニア症、リソソーム病、ケロイド、肥厚性瘢痕、筋ジストロフィー、または脊髄損傷の治療のための前記医薬組成物の使用を説明する添付文書又はラベルを含むキットが提供される。
本発明の一側面は、医薬組成物が容器に収容されてなる包装体の製造方法であり、2μg以上8μg以下の糖分解酵素を含む溶液を容器に収容する第1工程と、前記溶液を凍結乾燥して単位用量の医薬組成物を得る第2工程とを含む、製造方法に関する。
1)コンドロイチナーゼABCの調製
コンドロイチナーゼABCは、特開平6-153947号公報に記載の方法に準じて調製した。すなわち、プロテウス・ブルガリスの培養上清から精製することによって製造した。得られたコンドロイチナーゼABCの力価は、0.4U/μgであった。
コンドロイチナーゼABCの酵素活性は以下の方法で測定した。
酵素試料(コンドロイチナーゼABC)を0.01%(w/v)カゼイン試薬(20mMリン酸緩衝液)で4000倍希釈した。この希釈された酵素試料100μLに基質溶液400μL(3mg/mlコンドロイチン硫酸エステルナトリウム(日本薬局方外医薬品規格)、50mM 2-アミノ-2-ヒドロキシメチル-1,3-プロパンジオール、50mM酢酸ナトリウム、pH8)を加えて混和した。溶液を37℃で20分間反応させた後、100℃の水浴中で1分間加熱した。室温まで冷却後、0.05M 塩酸を5.0mL加え、試料溶液を調製した。コンドロイチナーゼABC標準物質を0.01%(w/v)カゼイン試薬で400倍希釈した。この希釈されたコンドロイチナーゼABC標準物質の溶液100μLに対し、試料溶液の調製と同様の操作を行い、標準溶液を調製した。また、0.01%(w/v)カゼイン試薬100μLに対し、試料溶液の調製と同様の操作を行い、対照溶液を調製した。試料溶液、標準溶液並びに対照溶液につき、紫外可視吸光度測定法により、波長232nmにおける吸光度AT、AS、およびABを測定し、下記式により酵素溶液活性(U/mL)を求めた。ここで酵素溶液活性は、単位液量当たりの酵素活性である。
AT:試料溶液の吸光度
AB:対照溶液の吸光度
AS:標準溶液の吸光度
Us:コンドロチナーゼABC標準物質の酵素溶液活性(U/mL)
以下の組成となるよう、酵素用緩衝液を用意した。
(組成;注射用蒸留水1L中)
リン酸水素ナトリウム水和物(リン酸水素ニナトリウム) 1.125mg
リン酸ニ水素ナトリウム 0.3mg
スクロース 5mg
ポリエチレングリコール3350 10mg
pH:6.5以上7.5以下。
酵素用緩衝液を用いて調製したコンドロチナーゼABC溶液を、酵素量が以下になるように3mlサイズのガラスバイアル(SCHOTT社製)に収容した:
試料1: 1.3μg/バイアル(0.5U/バイアル)
試料2: 2.5μg/バイアル(1.00U/バイアル)
試料3: 5.0μg/バイアル(2.00U/バイアル)
試料4: 9.1μg/バイアル(3.63U/バイアル)
工程1:常圧下で、温度を室温からマイナス35℃に冷却させ、試料を凍結させた。
工程2:温度マイナス35℃、常圧の状態を30分間維持した。
工程3:温度マイナス35℃、真空度13.3Paの状態を5時間維持した。
工程4:真空度を13.3Paに維持したまま、温度をマイナス35℃から25℃に昇温させた。
工程5:温度25℃、真空度13.3Paの状態を5時間維持した。
酵素用緩衝液を用いてコンドロチナーゼABC溶液を調製した。この調製した酵素溶液を、酵素量が1.5U/バイアルとなるように試験例1と同様にガラスバイアルに収容し、凍結乾燥した(水分含量2%(w/w)以下)。凍結乾燥後、窒素ガスでバイアル内を復圧し、ゴム栓を打栓し、単位用量製剤を得た。
試験例1の方法に準じて単位用量製剤(1.5U/バイアル)を得た。得られた単位用量製剤を、以下の条件1又は2で貯蔵した。各貯蔵期間後の酵素の力価を求めた。
条件2):5℃±3℃、遮光
本出願は、2018年2月28日付で日本国特許庁に出願された特願2018-35884号に基づく優先権を主張し、その内容は参照によって全体として本出願に組み込まれる。本明細書に記載された全ての文献、特許出願、及び技術規格は、個々の文献、特許出願、及び技術規格が参照により取り込まれることが具体的かつ個々に記された場合と同程度に、本明細書に参照により取り込まれる。
Claims (7)
- 力価が0.3ユニット/μg以上である凍結乾燥された糖分解酵素を有効成分として含み、
前記糖分解酵素量が2μg以上8μg以下の単位用量製剤である、医薬組成物。 - 酵素活性が4ユニット以下である、請求項1に記載の医薬組成物。
- 5℃±3℃で12ヶ月以上の貯蔵安定性を有する、請求項1または請求項2に記載の医薬組成物。
- 請求項1から請求項3のいずれか1項に記載の医薬組成物が容器に収容されてなる、包装体。
- 医薬組成物が容器に収容されてなる包装体の製造方法であり、
2μg以上8μg以下の糖分解酵素を含む溶液を容器に収容する工程と、
前記溶液を凍結乾燥して単位用量の医薬組成物を得る工程とを含む、製造方法。 - 前記医薬組成物は、力価が0.3ユニット/μg以上の糖分解酵素を含む、請求項5に記載の製造方法。
- 前記容器に収容される溶液の酵素活性が4ユニット以下である、請求項5または請求項6に記載の製造方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112020016631-6A BR112020016631B1 (pt) | 2018-02-28 | 2019-02-27 | Método para produção de uma embalagem |
RU2020131273A RU2788173C2 (ru) | 2018-02-28 | 2019-02-27 | Фармацевтическая композиция, упаковка и способ ее получения |
CN201980013994.1A CN111727050A (zh) | 2018-02-28 | 2019-02-27 | 药物组合物、包装体及其制造方法 |
CA3089180A CA3089180A1 (en) | 2018-02-28 | 2019-02-27 | Pharmaceutical composition, package, and method for producing the same |
KR1020207026957A KR20200126993A (ko) | 2018-02-28 | 2019-02-27 | 의약 조성물, 포장체 및 그 제조 방법 |
JP2020503548A JP7321142B2 (ja) | 2018-02-28 | 2019-02-27 | 医薬組成物、包装体及びその製造方法 |
AU2019228917A AU2019228917B2 (en) | 2018-02-28 | 2019-02-27 | Pharmaceutical composition, package, and method for manufacturing same |
EP19760102.4A EP3760219A4 (en) | 2018-02-28 | 2019-02-27 | PHARMACEUTICAL COMPOSITION, PACKAGING AND METHOD OF MANUFACTURING IT |
US16/975,546 US11648299B2 (en) | 2018-02-28 | 2019-02-27 | Pharmaceutical composition, package and method for producing the same |
KR1020247009518A KR20240042235A (ko) | 2018-02-28 | 2019-02-27 | 의약 조성물, 포장체 및 그 제조 방법 |
US18/133,168 US20230263871A1 (en) | 2018-02-28 | 2023-04-11 | Pharmaceutical composition, package and method for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-035884 | 2018-02-28 | ||
JP2018035884 | 2018-02-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/975,546 A-371-Of-International US11648299B2 (en) | 2018-02-28 | 2019-02-27 | Pharmaceutical composition, package and method for producing the same |
US18/133,168 Continuation US20230263871A1 (en) | 2018-02-28 | 2023-04-11 | Pharmaceutical composition, package and method for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019167983A1 true WO2019167983A1 (ja) | 2019-09-06 |
Family
ID=67805072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/007437 WO2019167983A1 (ja) | 2018-02-28 | 2019-02-27 | 医薬組成物、包装体及びその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11648299B2 (ja) |
EP (1) | EP3760219A4 (ja) |
JP (1) | JP7321142B2 (ja) |
KR (2) | KR20240042235A (ja) |
CN (1) | CN111727050A (ja) |
AU (1) | AU2019228917B2 (ja) |
CA (1) | CA3089180A1 (ja) |
TW (1) | TW202000228A (ja) |
WO (1) | WO2019167983A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135851A (ja) * | 1992-10-26 | 1994-05-17 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 |
JPH06153947A (ja) | 1992-06-26 | 1994-06-03 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc、その製造法及び医薬組成物 |
JPH0767642A (ja) * | 1993-09-03 | 1995-03-14 | Seikagaku Kogyo Co Ltd | 酵素組成物 |
JPH11193245A (ja) * | 1997-12-26 | 1999-07-21 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc組成物 |
JPH11236336A (ja) * | 1997-05-02 | 1999-08-31 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物 |
WO2012081227A1 (ja) | 2010-12-13 | 2012-06-21 | 生化学工業株式会社 | 椎間板ヘルニア治療剤 |
JP2018035884A (ja) | 2016-08-31 | 2018-03-08 | ナブテスコ株式会社 | スプール弁および弁システム |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3140797B2 (ja) * | 1991-04-26 | 2001-03-05 | 生化学工業株式会社 | 安定化コンドロイチナーゼabc、その保存方法及び治療剤 |
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
US6001630A (en) | 1992-06-26 | 1999-12-14 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896 |
JP3841121B2 (ja) * | 1997-02-28 | 2006-11-01 | スズキ株式会社 | 自動車のステアリング支持構造 |
EP0875253B1 (en) | 1997-05-02 | 2005-04-06 | Seikagaku Corporation | Chondroitinase compositions |
TWI319322B (en) | 2003-11-13 | 2010-01-11 | Ono Pharmaceutical Co | Frozen-dried preperation containing prostaglandin |
JP2008050320A (ja) | 2006-08-28 | 2008-03-06 | Toray Ind Inc | インターフェロン−β含有医薬組成物 |
US20100168011A1 (en) | 2006-12-12 | 2010-07-01 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations and Methods for Making the Same |
JP5636536B2 (ja) * | 2008-04-14 | 2014-12-10 | 国立大学法人名古屋大学 | 神経因性疼痛の改善剤 |
RU2014153544A (ru) | 2012-05-28 | 2016-07-20 | Намикос Корпорейшн | Стеклянный контейнер и способ его изготовления |
-
2019
- 2019-02-27 WO PCT/JP2019/007437 patent/WO2019167983A1/ja active Application Filing
- 2019-02-27 EP EP19760102.4A patent/EP3760219A4/en active Pending
- 2019-02-27 KR KR1020247009518A patent/KR20240042235A/ko active Search and Examination
- 2019-02-27 AU AU2019228917A patent/AU2019228917B2/en active Active
- 2019-02-27 CA CA3089180A patent/CA3089180A1/en active Pending
- 2019-02-27 KR KR1020207026957A patent/KR20200126993A/ko active IP Right Grant
- 2019-02-27 TW TW108106806A patent/TW202000228A/zh unknown
- 2019-02-27 CN CN201980013994.1A patent/CN111727050A/zh active Pending
- 2019-02-27 US US16/975,546 patent/US11648299B2/en active Active
- 2019-02-27 JP JP2020503548A patent/JP7321142B2/ja active Active
-
2023
- 2023-04-11 US US18/133,168 patent/US20230263871A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06153947A (ja) | 1992-06-26 | 1994-06-03 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc、その製造法及び医薬組成物 |
JPH06135851A (ja) * | 1992-10-26 | 1994-05-17 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 |
JPH0767642A (ja) * | 1993-09-03 | 1995-03-14 | Seikagaku Kogyo Co Ltd | 酵素組成物 |
JPH11236336A (ja) * | 1997-05-02 | 1999-08-31 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物 |
JPH11193245A (ja) * | 1997-12-26 | 1999-07-21 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc組成物 |
WO2012081227A1 (ja) | 2010-12-13 | 2012-06-21 | 生化学工業株式会社 | 椎間板ヘルニア治療剤 |
JP2018035884A (ja) | 2016-08-31 | 2018-03-08 | ナブテスコ株式会社 | スプール弁および弁システム |
Also Published As
Publication number | Publication date |
---|---|
AU2019228917A1 (en) | 2020-08-13 |
US11648299B2 (en) | 2023-05-16 |
CA3089180A1 (en) | 2019-09-06 |
US20200397876A1 (en) | 2020-12-24 |
AU2019228917B2 (en) | 2023-08-24 |
BR112020016631A2 (pt) | 2020-12-15 |
KR20240042235A (ko) | 2024-04-01 |
JP7321142B2 (ja) | 2023-08-04 |
JPWO2019167983A1 (ja) | 2021-03-04 |
EP3760219A4 (en) | 2021-08-18 |
KR20200126993A (ko) | 2020-11-09 |
EP3760219A1 (en) | 2021-01-06 |
RU2020131273A (ru) | 2022-03-28 |
CN111727050A (zh) | 2020-09-29 |
TW202000228A (zh) | 2020-01-01 |
US20230263871A1 (en) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2246033C (en) | Therapeutic agent for herniated intervertebral disc | |
EP0875253B1 (en) | Chondroitinase compositions | |
EP0576294A2 (en) | Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same | |
EP1220685B1 (en) | Pharmaceutical compositions of fibrinolytic agent | |
JP2023171428A (ja) | 包装体およびその製造方法 | |
JP4172842B2 (ja) | コンドロイチナーゼ組成物 | |
JP7321142B2 (ja) | 医薬組成物、包装体及びその製造方法 | |
RU2788173C2 (ru) | Фармацевтическая композиция, упаковка и способ ее получения | |
RU2798169C2 (ru) | Упаковка и способ ее получения | |
BR112020016631B1 (pt) | Método para produção de uma embalagem | |
JP4728459B2 (ja) | 椎間板ヘルニア治療剤 | |
JP4790692B2 (ja) | 顆粒球又はマクロファージの浸潤及び出現促進剤 | |
JPH0767642A (ja) | 酵素組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19760102 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3089180 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019228917 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2020503548 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019228917 Country of ref document: AU Date of ref document: 20190227 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207026957 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019760102 Country of ref document: EP Effective date: 20200928 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020016631 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020016631 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200814 |